| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -12,350 | -5,300 | -12,250 | -15,960 | -10,350 |
| Net Income Growth | -133.02% | +56.73% | +23.25% | -54.20% | -319.03% |
Dogwood Therapeutics Inc (DWTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Dogwood Therapeutics Inc. is a biopharmaceutical company. It engages in developing a new class of non-opioid analgesics. The company focuses on the development of Halneuron, IMC-1 and IMC-2. Dogwood Therapeutics Inc., formerly known as Virios Therapeutics Inc., is based in Alpharetta, GA.
Fiscal Year End Date: 12/31